{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:47:47Z","timestamp":1778597267024,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11033-019-04689-8","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T11:44:55Z","timestamp":1550231095000},"page":"2307-2325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phytosterols and triterpenes from Morinda lucida Benth. exhibit binding tendency against class I HDAC and HDAC7 isoforms"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-5922","authenticated-orcid":false,"given":"Ahmed Adebayo","family":"Ishola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-3798","authenticated-orcid":false,"given":"Kayode Ezekiel","family":"Adewole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"4689_CR1","doi-asserted-by":"publisher","unstructured":"Reddy DS, Wu X, Golub VM et al (2018) Measuring histone deacetylase inhibition in the brain. Curr Protoc Pharmacol 1\u201314. https:\/\/doi.org\/10.1002\/cpph.41","DOI":"10.1002\/cpph.41"},{"key":"4689_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu10060731","volume":"10","author":"AK Singh","year":"2018","unstructured":"Singh AK, Bishayee A, Pandey AK (2018) Targeting histone deacetylases with natural and synthetic agents: an emerging strategy. Nutrients 10:1\u201331. https:\/\/doi.org\/10.3390\/nu10060731","journal-title":"Nutrients"},{"key":"4689_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4172\/2161-0444.1000252","volume":"5","author":"S Kumar","year":"2015","unstructured":"Kumar S, Ahmad M, Waseem M, Pandey AK (2015) Drug targets for cancer treatment: an overview. Med Chem (Los Angeles) 5:115\u2013123","journal-title":"Med Chem (Los Angeles)"},{"key":"4689_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12906-016-1147-4","volume":"16","author":"U Sharma","year":"2016","unstructured":"Sharma U, Sharma A, Pandey AK (2016) Medicinal attributes of major phenylpropanoids present in cinnamon. BMC Complement Altern Med 16:156","journal-title":"BMC Complement Altern Med"},{"key":"4689_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18:1\u201325. https:\/\/doi.org\/10.3390\/ijms18071414","journal-title":"Int J Mol Sci"},{"key":"4689_CR6","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2018-0020","author":"SA Ganai","year":"2018","unstructured":"Ganai SA, Farooq Z, Banday S, Altaf M (2018) In silico approaches for investigating the binding propensity of apigenin and luteolin against class i HDAC isoforms. Future Med Chem. https:\/\/doi.org\/10.4155\/fmc-2018-0020","journal-title":"Future Med Chem"},{"key":"4689_CR7","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6:a018713","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4689_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","volume":"6","author":"B Barneda-Zahonero","year":"2012","unstructured":"Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Mol Oncol 6:579\u2013589. https:\/\/doi.org\/10.1016\/j.molonc.2012.07.003","journal-title":"Mol Oncol"},{"key":"4689_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"A Ruijter De","year":"2003","unstructured":"De Ruijter A, Van Gennip A, Caron H et al (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737\u2013749","journal-title":"Biochem J"},{"key":"4689_CR10","first-page":"2441","volume":"16","author":"S Ganai","year":"2016","unstructured":"Ganai S (2016) Novel approaches towards designing of isoform-selective inhibitors against class ii histone deacetylases: the acute requirement for targetted anticancer therapy. CurrTopMedChem 16:2441\u20132452","journal-title":"CurrTopMedChem"},{"key":"4689_CR11","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","volume":"20","author":"M Mottamal","year":"2015","unstructured":"Mottamal M, Zheng S, Huang T, Wang G (2015) Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20:3898\u20133941","journal-title":"Molecules"},{"key":"4689_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1:19\u201325. https:\/\/doi.org\/10.1016\/j.molonc.2007.01.001","journal-title":"Mol Oncol"},{"key":"4689_CR13","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"A Wilson","year":"2006","unstructured":"Wilson A, Byun D, Popova N (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281:13548\u201313558","journal-title":"J Biol Chem"},{"key":"4689_CR14","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1038\/emboj.2010.264","volume":"29","author":"S Lagger","year":"2010","unstructured":"Lagger S, Meunier DMM et al (2010) Crucial function ofhistone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J 29:3992\u20134007","journal-title":"EMBO J"},{"key":"4689_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pros.20022","volume":"59","author":"K Halkidou","year":"2004","unstructured":"Halkidou K, Gaughan L, Cook S et al (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177\u2013189","journal-title":"Prostate"},{"key":"4689_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","volume":"113","author":"J Song","year":"2005","unstructured":"Song J, Noh J, Lee J (2005) Increased expression ofhistone deacetylase 2 is found in human gastric cancer. APMIS 113:264\u2013268","journal-title":"APMIS"},{"key":"4689_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","volume":"12","author":"B Huang","year":"2005","unstructured":"Huang B, Laban M, Leung C (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent ofhistone deacetylase 1. Cell Death Differ 12:395\u2013404","journal-title":"Cell Death Differ"},{"key":"4689_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/1471-2407-13-215","volume":"13","author":"BM Muller","year":"2013","unstructured":"Muller BM, Jana LKA et al (2013) Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression ofHDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13:215","journal-title":"BMC Cancer"},{"key":"4689_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/mc.20373","volume":"47","author":"C Spurling","year":"2008","unstructured":"Spurling C, Godman C, Noonan E et al (2008) HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 47:137\u2013147","journal-title":"Mol Carcinog"},{"key":"4689_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","volume":"5","author":"I Oehme","year":"2009","unstructured":"Oehme I, Deubzer H, Wegener D (2009) Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 5:91\u201399","journal-title":"Clin Cancer Res"},{"key":"4689_CR21","first-page":"677","volume":"25","author":"S Park","year":"2011","unstructured":"Park S, Jun J, Jeong K (2011) Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25:677\u20131681","journal-title":"Oncol Rep"},{"key":"4689_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/jop.12560","volume":"46","author":"M-Y Ahn","year":"2017","unstructured":"Ahn M-Y, Yoon J-H (2017) Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. J Oral Pathol Med 46:276\u2013283. https:\/\/doi.org\/10.1111\/ijlh.12426","journal-title":"J Oral Pathol Med"},{"key":"4689_CR23","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/mc.20866","volume":"51","author":"M Pandey","year":"2012","unstructured":"Pandey M, Kaur P, Shukla S et al (2012) Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol Carcinog 51:952\u2013962","journal-title":"Mol Carcinog"},{"key":"4689_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejphar.2010.10.063","volume":"651","author":"S Attoub","year":"2011","unstructured":"Attoub S, Hassan A, Vanhoecke B (2011) Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol 651:18\u201325","journal-title":"Eur J Pharmacol"},{"key":"4689_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1381612823666171114165051","volume":"24","author":"SS Soflaei","year":"2018","unstructured":"Soflaei SS, Momtazi-Borojeni AA, Majeed M et al (2018) Curcumin: a natural Pan-HDAC inhibitor in cancer. Curr Pharm Des 24:123\u2013129. https:\/\/doi.org\/10.2174\/1381612823666171114165051","journal-title":"Curr Pharm Des"},{"key":"4689_CR26","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.2147\/DDDT.S78276","volume":"9","author":"K Murugan","year":"2015","unstructured":"Murugan K, Sangeetha S, Ranjitha S et al (2015) HDACiDB: a database for histone deacetylase inhibitors. Drug Des Devel Ther 9:2257\u20132264","journal-title":"Drug Des Devel Ther"},{"key":"4689_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jep.2007.06.024","volume":"113","author":"AA Sowemimo","year":"2007","unstructured":"Sowemimo AA, Fakoya FA, Awopetu I et al (2007) Toxicity and mutagenic activity of some selected Nigerian plants. J Ethnopharmacol 113:427\u2013432. https:\/\/doi.org\/10.1016\/j.jep.2007.06.024","journal-title":"J Ethnopharmacol"},{"key":"4689_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jep.2010.01.009","volume":"128","author":"JS Ashidi","year":"2010","unstructured":"Ashidi JS, Houghton PJ, Hylands PJ, Efferth T (2010) Ethnobotanical survey and cytotoxicity testing of plants of South-western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp. leaves. J Ethnopharmacol 128:501\u2013512. https:\/\/doi.org\/10.1016\/j.jep.2010.01.009","journal-title":"J Ethnopharmacol"},{"key":"4689_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1055\/s-0028-1099378","volume":"26","author":"JI Durodola","year":"1974","unstructured":"Durodola JI (1974) Anti-neoplastic property of crystalline compound extracted from Morinda lucida. Planta Med 26:208\u2013211","journal-title":"Planta Med"},{"key":"4689_CR30","first-page":"4281","volume":"5","author":"R Appiah-opong","year":"2016","unstructured":"Appiah-opong R, Tuffour I, Annor GK et al (2016) Antiproliferative, antioxidant activities and apoptosis induction by Morinda lucida and Taraxacum officinale in human HL-60 leukemia cells. J Glob Biosci 5:4281\u20134291","journal-title":"J Glob Biosci"},{"key":"4689_CR31","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.5897\/AJB11.862","volume":"11","author":"NE Nweze","year":"2012","unstructured":"Nweze NE (2012) In vitro anti-trypanosomal activity of Morinda lucida leaves. African J Biotechnol 11:1812\u20131817. https:\/\/doi.org\/10.5897\/AJB11.862","journal-title":"African J Biotechnol"},{"key":"4689_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6882-14-325","volume":"14","author":"M Samje","year":"2014","unstructured":"Samje M, Metuge J, Mbah J et al (2014) In vitro anti- Onchocerca ochengi activities of extracts and chromatographic fractions of Craterispermum laurinum and Morinda lucida. BMC Complement Altern Med 14:1\u201312. https:\/\/doi.org\/10.1186\/1472-6882-14-325","journal-title":"BMC Complement Altern Med"},{"key":"4689_CR33","doi-asserted-by":"publisher","unstructured":"Suzuki M, Tung HN, Kwofie KD et al (2015) New anti-trypanosomal active tetracyclic iridoid isolated from Morinda lucida Benth. Biorgan Med Chem Lett http:\/\/dx:1\u20134. https:\/\/doi.org\/10.1016\/j.bmcl.2015.05.003","DOI":"10.1016\/j.bmcl.2015.05.003"},{"key":"4689_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle NM, Banck M, James CA et al (2011) Open babel: an open chemical toolbox. J Cheminform 3:33. https:\/\/doi.org\/10.1186\/1758-2946-3-33","journal-title":"J Cheminform"},{"key":"4689_CR35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461","journal-title":"J Comput Chem"},{"key":"4689_CR36","doi-asserted-by":"publisher","DOI":"10.2174\/138920007780866799","author":"DF McGinnity","year":"2007","unstructured":"McGinnity DF, Collington J, Austin RP, Riley RJ (2007) Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab. https:\/\/doi.org\/10.2174\/138920007780866799","journal-title":"Curr Drug Metab"},{"key":"4689_CR37","doi-asserted-by":"publisher","DOI":"10.2174\/156802611794480927","author":"M Paul Gleeson","year":"2011","unstructured":"Paul Gleeson M, Hersey A, Hannongbua S (2011) In-silico ADME models: a general assessment of their utility in drug discovery applications. Curr Top Med Chem. https:\/\/doi.org\/10.2174\/156802611794480927","journal-title":"Curr Top Med Chem"},{"key":"4689_CR38","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1021\/ci500467k","volume":"54","author":"A Daina","year":"2014","unstructured":"Daina A, Michielin O, Zoete V (2014) ILOGP: a simple, robust, and efficient description of n-octanol\/water partition coefficient for drug design using the GB\/SA approach. J Chem Inf Model 54:3284\u20133301. https:\/\/doi.org\/10.1021\/ci500467k","journal-title":"J Chem Inf Model"},{"key":"4689_CR39","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/cmdc.201600182","volume":"11","author":"A Daina","year":"2016","unstructured":"Daina A, Zoete V (2016) A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 11:1117\u20131121","journal-title":"ChemMedChem"},{"key":"4689_CR40","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"issue":"8","key":"4689_CR41","doi-asserted-by":"publisher","first-page":"30163034","DOI":"10.3390\/ijms11083016","volume":"11","author":"SY Huang","year":"2010","unstructured":"Huang SY, Zou X (2010) Advances and challenges in protein-ligand docking. Int J Mol Sci 11(8):3016\u20133034","journal-title":"Int J Mol Sci"},{"key":"4689_CR42","unstructured":"Raj RA, John Milton MC, Prakasam A et al (2018) In silico molecular docking of bioactive compound Pregnan-20-one,5,6-epoxy-3,17,dihydroxy-16 methyl-[3a,5a,6a,16a] with brain cancer protein(1qh4): a promising molecular target. 9:51\u201355"},{"issue":"1","key":"4689_CR43","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1038\/s41598-017-03417-1","volume":"7","author":"KC Hsu","year":"2017","unstructured":"Hsu KC, Liu CY, Lin TE et al (2017) Novel class IIA-selective histone deacetylase inhibitors discovered using an in silico virtual screening approach. Sci Rep 7(1):3228. https:\/\/doi.org\/10.1038\/s41598-017-03417-1","journal-title":"Sci Rep"},{"issue":"1","key":"4689_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","volume":"52","author":"S Yoon","year":"2016","unstructured":"Yoon S, Eom GH (2016) HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J 52(1):1 https:\/\/doi.org\/10.4068\/cmj.2016.52.1.1","journal-title":"Chonnam Med J"},{"key":"4689_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-S13-S23","author":"USF Tambunan","year":"2011","unstructured":"Tambunan USF, Bramantya N, Parikesit AA (2011) In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC). BMC Bioinform. https:\/\/doi.org\/10.1186\/1471-2105-12-S13-S23","journal-title":"BMC Bioinform"},{"key":"4689_CR46","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1093\/jn\/130.9.2127","volume":"130","author":"AB Awad","year":"2000","unstructured":"Awad AB, Fink CS (2000) Phytosterols as anticancer dietary components: evidence and mechanism of action. J Nutr 130:2127\u20132130","journal-title":"J Nutr"},{"key":"4689_CR47","first-page":"433","volume":"42","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Luo Z, Shi H et al (2017) Research advance of functional plant pharmaceutical cycloartenol about pharmacological and physiological activity. J Chinese Mater medica 42:433\u2013437","journal-title":"J Chinese Mater medica"},{"key":"4689_CR48","doi-asserted-by":"publisher","DOI":"10.2174\/1871520618666180315090949","author":"I Silva da","year":"2018","unstructured":"da Silva I, Kaluderovic G, de Oliveira P et al (2018) Apoptosis caused by triterpenes and phytosterols and antioxidant activity of an enriched flavonoid extract from Passiflora mucronata. Anticancer Agents Med Chem. https:\/\/doi.org\/10.2174\/1871520618666180315090949","journal-title":"Anticancer Agents Med Chem"},{"key":"4689_CR49","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/ptr.2189","volume":"21","author":"J Choi","year":"2007","unstructured":"Choi J, Lee E, Lee H et al (2007) Identification of campesterol from Chrysanthemum coronarium L. and its antiangiogenic activities. Phyther Res 21:954\u2013959. https:\/\/doi.org\/10.1002\/ptr","journal-title":"Phyther Res"},{"key":"4689_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0189628","volume":"12","author":"T Kangsamaksin","year":"2017","unstructured":"Kangsamaksin T, Chaithongyot S, Wootthichairangsan C (2017) Lupeol and stigmasterol suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor necrosis factor- \u03b1. PLoS One 12:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0189628","journal-title":"PLoS One"},{"key":"4689_CR51","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/CAD.0b013e328330fd90","volume":"20","author":"A Petronelli","year":"2009","unstructured":"Petronelli A, Pannitteri G, Testa U (2009) Triterpenoids as new promising anticancer drugs. Anticancer Drugs 20:880\u2013892. https:\/\/doi.org\/10.1097\/CAD.0b013e328330fd90","journal-title":"Anticancer Drugs"},{"key":"4689_CR52","first-page":"6","volume":"72","author":"I Chen","year":"2009","unstructured":"Chen I, Lu M, Du Y et al (2009) Cytotoxic triterpenoids from the stems of Microtropis japonica. J Nat Prod 72:6\u201311","journal-title":"J Nat Prod"},{"key":"4689_CR53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","volume":"44","author":"CA Lipinski","year":"2000","unstructured":"Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235\u2013249","journal-title":"J Pharmacol Toxicol Methods"},{"key":"4689_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0378-8741(95)90032-2","volume":"49","author":"J Liu","year":"1995","unstructured":"Liu J (1995) Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49:57\u201368","journal-title":"J Ethnopharmacol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-019-04689-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T20:31:56Z","timestamp":1720989116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-019-04689-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4689"],"URL":"https:\/\/doi.org\/10.1007\/s11033-019-04689-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}